| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| C H Ashto. Adverse effects of cannabis and cannabinoids. British journal of anaesthesia. vol 83. issue 4. 2000-03-02. PMID:10673884. |
adverse effects of cannabis and cannabinoids. |
2000-03-02 |
2023-08-12 |
Not clear |
| M A ElSohly, S A Ross, Z Mehmedic, R Arafat, B Yi, B F Banaha. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of forensic sciences. vol 45. issue 1. 2000-02-25. PMID:10641915. |
potency trends of delta9-thc and other cannabinoids in confiscated marijuana from 1980-1997. |
2000-02-25 |
2023-08-12 |
Not clear |
| M A ElSohly, S A Ross, Z Mehmedic, R Arafat, B Yi, B F Banaha. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of forensic sciences. vol 45. issue 1. 2000-02-25. PMID:10641915. |
the analysis of 35,312 cannabis preparations confiscated in the usa over a period of 18 years for delta-9-tetrahydrocannabinol (delta9-thc) and other major cannabinoids is reported. |
2000-02-25 |
2023-08-12 |
Not clear |
| M A ElSohly, S A Ross, Z Mehmedic, R Arafat, B Yi, B F Banaha. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of forensic sciences. vol 45. issue 1. 2000-02-25. PMID:10641915. |
other major cannabinoids [cannabidiol (cbd), cannabinol (cbn), and cannabichromene (cbc)] showed no significant change in their concentration over the years. |
2000-02-25 |
2023-08-12 |
Not clear |
| E S Onaivi, G Chaudhuri, A S Abaci, M Parker, D H Manier, P R Martin, J R Hubbar. Expression of cannabinoid receptors and their gene transcripts in human blood cells. Progress in neuro-psychopharmacology & biological psychiatry. vol 23. issue 6. 2000-02-03. PMID:10621950. |
normal human volunteers who do not use marijuana have genes that encode for the marijuana (cannabinoid) receptor proteins. |
2000-02-03 |
2023-08-12 |
human |
| G A Bohme, M Laville, C Ledent, M Parmentier, A Imperat. Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience. vol 95. issue 1. 2000-01-31. PMID:10619457. |
marijuana is known to affect learning and memory in humans, and cannabinoids block long-term potentiation in the hippocampus, a model for the synaptic changes that are believed to underlie memory at the cellular level. |
2000-01-31 |
2023-08-12 |
mouse |
| Z H Song, C A Slowe. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. The Journal of pharmacology and experimental therapeutics. vol 292. issue 1. 2000-01-27. PMID:10604940. |
it is known that marijuana smoking and administration of natural cannabinoids reduce intraocular pressure. |
2000-01-27 |
2023-08-12 |
Not clear |
| Z Járai, J A Wagner, K Varga, K D Lake, D R Compton, B R Martin, A M Zimmer, T I Bonner, N E Buckley, E Mezey, R K Razdan, A Zimmer, G Kuno. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proceedings of the National Academy of Sciences of the United States of America. vol 96. issue 24. 2000-01-06. PMID:10570211. |
here we show that "abnormal cannabidiol" (abn-cbd) is a neurobehaviorally inactive cannabinoid that does not bind to cb1 receptors, yet causes sr141716a-sensitive hypotension and mesenteric vasodilation in wild-type mice and in mice lacking cb1 receptors or both cb1 and cb2 receptors. |
2000-01-06 |
2023-08-12 |
mouse |
| R G Pertwe. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forschende Komplementarmedizin. vol 6 Suppl 3. 2000-01-05. PMID:10575283. |
cannabis and cannabinoids: pharmacology and rationale for clinical use. |
2000-01-05 |
2023-08-12 |
Not clear |
| R G Pertwe. Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forschende Komplementarmedizin. vol 6 Suppl 3. 2000-01-05. PMID:10575283. |
for the therapeutic potential of cannabis or cb1 receptor agonists to be fully exploited, it will be important to establish objectively and conclusively (a) whether these agents have efficacy against selected symptoms that is of clinical significance and, if so, whether the benefits outweigh the risks, (b) whether cannabis has therapeutic advantages over individual cannabinoids, (c) whether there is a need for additional drug treatments to manage any of the disorders against which cannabinoids are effective, and (d) whether it will be possible to develop drugs that have reduced psychotropic activity and yet retain the ability to act through cb1 receptors to produce their sought-after effects. |
2000-01-05 |
2023-08-12 |
Not clear |
| R W Gorte. Cancer cachexia and cannabinoids. Forschende Komplementarmedizin. vol 6 Suppl 3. 2000-01-05. PMID:10575285. |
there are strong indications that cannabis is better tolerated than thc alone, because cannabis contains several additional cannabinoids, like cannabidiol (cbd), which antagonize the psychotropic actions of thc, but do not inhibit the appetite-stimulating effect. |
2000-01-05 |
2023-08-12 |
Not clear |
| L Grinspoo. The future of medical marijuana. Forschende Komplementarmedizin. vol 6 Suppl 3. 2000-01-05. PMID:10575288. |
arrangements now being proposed for making cannabis constituents medically available include quasi-legal buyers clubs, restrictive classification as a prescription drug, the isolation of individual cannabinoids, and the manufacture of synthetic analogs. |
2000-01-05 |
2023-08-12 |
Not clear |
| F Grotenhermen, R Salle. [Cannabis and cannabinoids in medicine]. Forschende Komplementarmedizin. vol 6 Suppl 3. 2000-01-05. PMID:10627162. |
[cannabis and cannabinoids in medicine]. |
2000-01-05 |
2023-08-12 |
Not clear |
| J L Wile. Cannabis: discrimination of "internal bliss"? Pharmacology, biochemistry, and behavior. vol 64. issue 2. 1999-12-20. PMID:10515300. |
the recent discovery of arachidonylethanolamide (anandamide), an endogenous ligand for cannabinoid receptors, and the synthesis of sr141716a, a cannabinoid antagonist selective for brain cannabinoid (cb1) receptors, have provided new tools to explore the mechanisms underlying cannabis abuse and dependence. |
1999-12-20 |
2023-08-12 |
Not clear |
| J L Wile. Cannabis: discrimination of "internal bliss"? Pharmacology, biochemistry, and behavior. vol 64. issue 2. 1999-12-20. PMID:10515300. |
drug discrimination is the animal model with the most predictive validity and specificity for investigation of the psychoactive effects of cannabinoids related to their abuse potential, because, unlike many other drugs of abuse, delta9-tetrahydrocannabinol (delta9-thc), the major psychoactive ingredient of marijuana, is not self-administered by animals. |
1999-12-20 |
2023-08-12 |
Not clear |
| J L Wile. Cannabis: discrimination of "internal bliss"? Pharmacology, biochemistry, and behavior. vol 64. issue 2. 1999-12-20. PMID:10515300. |
results of delta9-thc discrimination studies have revealed that the subjective effects of cannabis intoxication are pharmacologically selective for centrally active cannabinoid compounds, and that cannabis action at cb1 receptors is involved in medication of these effects. |
1999-12-20 |
2023-08-12 |
Not clear |
| J L Wile. Cannabis: discrimination of "internal bliss"? Pharmacology, biochemistry, and behavior. vol 64. issue 2. 1999-12-20. PMID:10515300. |
preliminary evidence from drug discrimination studies with more metabolically stable anandamide analogs have suggested that these differences in the discriminative stimulus effects of delta9-thc and anandamide-like cannabinoids are not entirely due to pharmacokinetic factors, but the exact role of "internal bliss" in cannabis intoxication and dependence is still not completely understood. |
1999-12-20 |
2023-08-12 |
Not clear |
| J M Sulliva. Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons. Journal of neurophysiology. vol 82. issue 3. 1999-11-01. PMID:10482747. |
cannabinoids, such as marijuana, are known to impair learning and memory perhaps through their actions in the hippocampus where cannabinoid receptors are expressed at high density. |
1999-11-01 |
2023-08-12 |
Not clear |
| E Po. Cannabinoids, endogenous ligands and synthetic analogs. Current opinion in chemical biology. vol 3. issue 4. 1999-09-16. PMID:10419842. |
the investigation of natural and synthetic cannabinoid ligands, including (-)-delta(9)-tetrahydrocannabinol, cannabinol, cannabidiol, hu-210, hu-211, ct3, cp 55, 940, win 55, 212-2, sr 14, 1716a, anandamide, 2-arachidonoylglycerol, and numerous novel analogs, has led to important findings that have contributed to a better understanding of the role of these compounds in physiological processes. |
1999-09-16 |
2023-08-12 |
Not clear |
| J L Mille. Panel sees medical potential in standardized cannabinoids but not in smoked marijuana. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 56. issue 10. 1999-09-10. PMID:10365716. |
panel sees medical potential in standardized cannabinoids but not in smoked marijuana. |
1999-09-10 |
2023-08-12 |
Not clear |